Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01396408
Title A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors NCIC Clinical Trials Group
Age Groups: senior | adult
Covered Countries CAN

Facility Status City State Zip Country Details
Tom Baker Cancer Centre Calgary Alberta T2N 4N2 Canada Details
Cross Cancer Institute Edmonton Alberta T6G 1Z2 Canada Details
BCCA - Cancer Centre for the Southern Interior Kelowna British Columbia V1Y 5L3 Canada Details
BCCA - Vancouver Cancer Centre Vancouver British Columbia V5Z 4E6 Canada Details
CancerCare Manitoba Winnipeg Manitoba R3E 0V9 Canada Details
QEII Health Sciences Centre Halifax Nova Scotia B3H 1V7 Canada Details
Izaak Walton Killam (IWK) Health Centre Halifax Nova Scotia B3K 6R8 Canada Details
Juravinski Cancer Centre at Hamilton Health Sciences Hamilton Ontario L8V 5C2 Canada Details
London Regional Cancer Program London Ontario N6A 4L6 Canada Details
Ottawa Hospital Research Institute Ottawa Ontario K1H 8L6 Canada Details
Hospital for Sick Children Toronto Ontario M5G 1X8 Canada Details
Univ. Health Network-Princess Margaret Hospital Toronto Ontario M5G 2M9 Canada Details
CHUM - Hopital Notre-Dame Montreal Quebec H2L 4M1 Canada Details
McGill University - Dept. Oncology Montreal Quebec H2W 1S6 Canada Details
CHU Sainte-Justine Montreal Quebec H3T 1C5 Canada Details
Allan Blair Cancer Centre Regina Saskatchewan S4T 7T1 Canada Details
Saskatoon Cancer Centre Saskatoon Saskatchewan S7N 4H4 Canada Details
*Shaded cells indicate that there was no data available from for the field